Alzheimer's disease

A collaboration of nephrologists and biochemists created the first structure of “megalin,” a critical protein in kidney and brain disorders.

By analyzing the changing genomes of short- and long-lived rockfish, scientists identified a new set of genes that might alter lifespan.

Drugs that target senescent cells could one day treat frailty, Alzheimer’s disease, or cancer.

The Alzheimer's disease research field has been beset by failed clinical trials and fraud. But researchers remain hopeful that a better understanding of the disease’s broader picture will lead to treatments.

Accuracy doesn’t only apply to isolated facts, but to the overall picture they paint.  

Exercise-induced molecules may inspire the next generation of neuroprotective drugs.

A new analysis shows huge variation in mutations for induced pluripotent stem cells, including some changes that can severely limit their ability to transform into other kinds of cells.

A once fringe theory that viral and bacterial infections trigger the neuroinflammation and cognitive decline associated with Alzheimer’s disease is gaining traction. If it proves true, available antimicrobials could be a long sought-after treatment for this neurodegenerative disease.

Scientists leverage the natural ability of antibodies to cross the blood-brain barrier and target proteins implicated in neurodegenerative disease.

LIVE August 26th, 2021 at 11:00 AM ET

In this webinar, experts will discuss new approaches to identify small therapeutic candidates targeting diabetes and Alzheimer’s disease.